"Gasping": Scientists Make Breakthrough Toward Full Cure for HIV
Researchers say they've taken a major step toward finding a cure for HIV.
As The Guardian reports, scientists at the Peter Doherty Institute for Infection and Immunity in Melbourne found a way to make the HIV virus visible, potentially laying the groundwork for ways to banish it from the body altogether.
As detailed in a paper published in the journal Nature Communications, the team developed a way to send messenger RNA into cells, to root out the hiding virus by fully enveloping it in a bubble of formulated fat called lipid nanoparticles (LNPs). The genetic molecules then instruct the cells to make the virus visible.
Author and Doherty Institute research fellow Paula Cevaal told the Guardian that it was "previously thought impossible" to deliver mRNA into HIV-containing white blood cells. But thanks to a new type of LNPs, dubbed LNP X, the team found a way for these cells to accept the mRNA.
"Our hope is that this new nanoparticle design could be a new pathway to an HIV cure," she added.
The human immunodeficiency virus attacks the human body's immune system and can lead to deadly AIDS if left untreated. Despite decades of research, there's still no effective cure for the disease; though a handful of patients have been fully cured of HIV, the treatments remain brutally complex and expensive.
While the number of people in the United States living with HIV has decreased since 2018, over 39,000 new patients were diagnosed in 2023.
The latest research came with such surprising findings that the team didn't believe it at first.
"We were overwhelmed by how [much of a] night and day difference it was — from not working before, and then all of a sudden it was working. And all of us were just sitting gasping like, 'wow,'" Cevaal told the Guardian.
While it's a promising step in the right direction, scientists still have to figure out whether making the hidden virus visible will cause the body's immune system to deal with it. Other possibilities include developing new ways to combine their findings with other gene therapies to ultimately cure HIV.
Before the latest technique can be used in humans, it would also have to be put through its paces, from animal experiments to human safety trials, a process that could easily take many years.
And Cevaal appears to be realistic about those chances.
"In the field of biomedicine, many things eventually don't make it into the clinic — that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality," she told the Guardian. "But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus."
"So from that point of view, we're very hopeful that we are also able to see this type of response in an animal, and that we could eventually do this in humans," she added.
Beyond HIV, the researchers are hoping their LNP-based mRNA delivery method could be applied to other diseases as well, including certain types of cancer.
More on HIV: Religious Conservatives Trying to End Insurance Coverage of Incredibly Effective Anti-HIV Drug
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Oakland County issues alert for measles exposure site in Rochester Hills
FOX 2 - The Oakland County Health Division is notifying the public about a Rochester Hills measles exposure site involving a person from another county. The exposure site is a medical office building at 3950 S. Rochester Road at the corner of South Boulevard on Tuesday, June 3, according to a release from the Oakland County Health Division. Anyone there between 8 a.m. and 7:30 p.m. may have been exposed to measles. If you think you were exposed to measles at this location on June 3, Immune Globulin (IG) treatment is effective within six days of exposure for high-risk individuals. Those considered high-risk include women who are pregnant, unvaccinated children under age 5 and those who have a weakened immune system due to illness and disease including diabetes or HIV, malnutrition and/or medications. If you are not eligible for IG, monitor symptoms through June 24. If symptoms develop, call ahead to your health care provider. Individuals born in or before 1957 are considered immune. Measles is a highly contagious, vaccine-preventable disease that is spread by direct person-to-person contact and through the air. The Health Division recommends unvaccinated individuals ages 1 year and older receive a measles vaccination to protect themselves and those around them. Anyone who doesn't have a record of two MMR vaccines, unsure if they've have been vaccinated, or unsure if you've had measles in the past, needs to contact their health care provider. Measles can live for up to two hours in the air where an infected person coughed or sneezed. Symptoms of measles usually begin 7-14 days after exposure, but can appear up to 21 days after exposure, and may include: High fever (may spike to over 104°F Cough Runny nose Red, watery eyes (conjunctivitis) Tiny white spots on the inner cheeks, gums and roof of mouth (Koplik Spots) 2-3 days after symptoms begin. A rash that is red, raised, blotchy; usually starts on face, spreads to trunk, arms and legs 3-5 days after symptoms begin. The MMR vaccine is available through some health care providers, Oakland County Health Division offices in Southfield and Pontiac, and many pharmacies. Health Division offices are located at the following addresses: North Oakland Health Center, 1200 N. Telegraph Road, Building 34 East, Pontiac South Oakland Health Center, 27725 Greenfield Road, Southfield. Health Division clinics hours are Monday, Wednesday and Friday 8:30 a.m. – 5 p.m. Tuesday 9:30 a.m. – 6 p.m. and Thursday 7:30 a.m. – 5 p.m. Visit for more information on measles, or contact Nurse on Call, 8:30 a.m. to 5 p.m. Monday through Friday, at 800-848-5533 or noc@
Yahoo
7 hours ago
- Yahoo
UCSD students protest Trump cuts to science research funding
SAN DIEGO (FOX 5/KUSI) — For the second time this year, students and faculty at the University of California, San Diego (UCSD) staged a protest outside Geisel Library, demanding the federal government reverse deep education funding cuts imposed by the Trump administration — cuts they say are threatening research, jobs and the future of scientific innovation. Dozens of protesters gathered on campus, holding signs and sharing personal stories about how the loss of federal research grants is impacting their work and well-being. Dozens possibly detained by federal officials amid immigration raids in Los Angeles 'This year has been filled with many moments of insecurity,' said Eleanor Ketterer-Sykes, a first-year Ph.D. student in the neuroscience program. 'UCSD is one of the best science schools in the country because of its renowned research labs, you have access to labs at the Salk Institute, Sanford and Scripps as well as the VA Hospital — but that future is in jeopardy.' The Trump administration has canceled hundreds of research grants in recent months, citing concerns over 'ideologically driven science.' The cuts have targeted studies ranging from HIV prevention to violence prevention in children. UCSD Chancellor Pradeep Khosla warned in an April letter that the university stands to lose between $75 million and $500 million annually as a result. 'As of May 30, there have been more than 150 federal grants terminated, resulting in a loss of $30 million,' said Lisa Eyler, a UCSD psychiatry professor. 'These cuts are already leading to layoffs among instructors, staff scientists, and support personnel like librarians.' 'No Kings Day' protests planned across California on June 14 The ripple effects could be felt beyond UCSD. Stanley Maloy, emeritus professor of microbiology at San Diego State University, said the cuts threaten the pipeline of future scientists and engineers. 'Reduced positions mean talented students are left behind,' Maloy said. 'As this innovation workforce dries up, our economy is going to suffer.' Eyler echoed those concerns, warning of a generational loss in scientific progress. 'There will be a gaping hole in the pipeline of future scientists, engineers and healthcare providers, which could result in the potential loss of an entire generation of great scientific thinkers,' she said. Thousands in San Diego protest cuts to federal education funds For Ketterer-Sykes, the issue is personal. She entered the neuroscience program hoping to make life-saving breakthroughs. 'So many people rely on scientific innovation — whether it be to find cures for diseases like tuberculosis or Alzheimer's disease,' she said. 'It really is vital to humanity.' While the exact financial toll remains uncertain, university leaders say the impact is already being felt — and may only get worse. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
12 hours ago
- Yahoo
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.